HOME > TOP STORIES
TOP STORIES
-
BUSINESS Sobi Japan Shoots for 8 to 9-Fold Growth by 2030 on Five Approvals
April 17, 2026
-
REGULATORY Unpacking “MFN”: Japan Listed as Reference Country in US Pricing Models
April 16, 2026
-
BUSINESS Sanofi Japan Sales Rise 4.5% in 2025 as Dupixent Widens Label
April 15, 2026
-
REGULATORY Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
April 14, 2026
-
BUSINESS AstraZeneca Lifts Japan Approval Target to 50-Plus by 2030 as Pipeline Advances
April 13, 2026
-
BUSINESS MSD Japan Eyes Up to 8 Approvals, 8-Plus Filings under New Chief
April 10, 2026
-
REGULATORY Japan OKs Listing of Exdensur, Aquipta, Tukysa, and More; New Price Rules Applied to Two
April 9, 2026
-
BUSINESS Rising Costs Squeeze Generic Firms, Spur Calls for Unprofitable Drug Re-Pricing in 2027
April 8, 2026
-
BUSINESS BMS Files to Fully Localize Breyanzi Production in Japan
April 8, 2026
-
REGULATORY Uncertainty Clouds Start of 6-Month CEA “Technical Discussions”
April 7, 2026
-
REGULATORY Pfizer Japan Chief Urges Applying 9.6% Growth Target to Domestic Market
April 7, 2026
-
BUSINESS Drug Makers Keep New Grad Hiring Largely Flat as Sales Rep Hiring Picks Up
April 6, 2026
-
BUSINESS Japan Drug Makers Vetting Impact as Trump Unveils Tariff Details
April 6, 2026
-
REGULATORY Trump Signs Off on Up to 100% Tariffs on Drugs; Japan Rate Set at 15%
April 3, 2026
-
BUSINESS Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
-
BUSINESS Human Judgment Still Key in the AI Era, Pharma Leaders Tell New Recruits
April 2, 2026
-
BUSINESS Pfizer Hails Adult Rollout of Prevenar 20 as “Milestone” for Public Health
April 1, 2026
-
ORGANIZATION JMA’s Ezawa Calls for “National Debate” on Drug Policy
March 31, 2026
-
ACADEMIA Japan Ophthalmology Society Flags Off-Label Concerns Ahead of Upneeq Launch
March 30, 2026
-
BUSINESS Otsuka to Acquire Transcend for US$700 Million, Snags PTSD Candidate
March 30, 2026
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
